Bain Capital Public Equity Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bain Capital Public Equity Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-241,408	Closed	-$41M	–	79
2018 Q2	$41M	Buy	241,408 +151,014	+167%	+$23.4M	2.77%	11
2018 Q1	$14.7M	Buy	90,394 +20,394	+29%	+$3.33M	1.07%	23
2017 Q4	$10.5M	Sell	70,000 -100,868	-59%	-$14.9M	0.76%	34
2017 Q3	$26M	Sell	170,868 -279,630	-62%	-$42.1M	1.64%	20
2017 Q2	$58.1M	Buy	450,498 +171,425	+61%	+$20.6M	3.49%	8
2017 Q1	$30.5M	Buy	+279,073	New	+$24.6M	2.16%	22

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Bain Capital Public Equity Management's VRTX Position: Q3 2018 in Review

Bain Capital Public Equity Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2018, closing a stake of 241,408 shares — an estimated $41M sold.

Bain Capital Public Equity Management first reported a position in VRTX in Q1 2017 and held it in 6 quarters. The position peaked at $58.1M in Q2 2017. 696 funds tracked by Wall St. Rank hold VRTX as of Q3 2018.

Bain Capital Public Equity Management reported no remaining Vertex Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Bain Capital Public Equity Management sold 241,408 Vertex Pharmaceuticals shares in Q3 2018, an estimated $41M.
Bain Capital Public Equity Management first reported a position in Vertex Pharmaceuticals in Q1 2017 and held it in 6 quarters.
Bain Capital Public Equity Management's Vertex Pharmaceuticals position peaked at $58.1M in Q2 2017.
696 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2018.

Based on Bain Capital Public Equity Management's 13F filing for Q3 2018, filed 14 Nov 2018.